Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12403134
Method for improving or enhancing cognition
granted -
US 12403192
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
granted -
US 12404508
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
granted -
US 12403090
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 12403202
Dosage of claudin-6 conjugates for cancer treatment
granted -
WO 2025184490
N-[4-FLUOR-5-[[(2S,4R)-4-[(6-MÉTHOXY-4-PYRIMIDNYL)OXY]-2-MÉTHYL-1-PYRROLIDINYL]MÉTHYL]-2-THIAZOLYL]ACÉTAMIDE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
granted -
US 12410225
Modulation of dendritic cell lineages
granted -
US 12412764
Substrate-accommodating container
granted -
US 12410153
Compounds, compositions and methods
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410249
Low dose antibody-based methods for treating hematologic malignancies
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12410398
Methods of human retinal progenitor cell isolation and culture
granted -
US 12410403
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12410430
Modulating apolipoprotein (A) expression
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12410474
Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient
granted -
US 12410442
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
granted -
US 12410399
Compositions and methods for treating retinal diseases
granted -
US 12409225
Ras inhibitors
granted -
US 12409188
Modulators of HSD17B13 expression
granted -
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12409227
Cochleates made with soy phosphatidylserine
granted -
US 12409205
Nanomolecules for the treatment of inflammatory bowel diseases
granted -
US 12409197
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 12409206
Use of cyclosporine analogues for treating fibrosis
granted -
US 12409167
Pharmaceutical combination comprising a selective S1P1 receptor agonist
granted -
US 12409181
Treatment for aortic aneurysms
granted -
US 12410209
Modified glucocorticoids
granted -
US 12410231
Natural killer cell products and methods
granted -
US 12410232
Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
granted -
US 12409224
Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12409220
Conjugate polypeptides and vaccines for inducing immune responses
granted -
US 12409228
Hydrogel drug delivery systems for the treatment of pediatric growth plate injuries
granted -
US 12410132
Antiplatelet drugs and uses thereof
granted -
US 12410170
2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds
granted -
US 12410137
Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
granted -
US 2025281584
ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS
granted -
WO 2025186043
FORMULATION PHARMACEUTIQUE POUR ANTICORPS ANTI-CCR8
granted -
US 12415861
Anti C-MET antibodies
granted -
US 12415863
Compositions and methods for treating cancer
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12415867
Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
granted -
US 12415995
Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
granted -
US 12416006
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
granted -
US 12416008
Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity using RNA aptamers
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.